4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Core Viewpoint - 4D Molecular Therapeutics reported advancements in its 4D-150 program, with accelerated timelines for clinical trials and a strong cash position to support operations into 2028 [1][2][8]. Recent Corporate Highlights - The company streamlined operations, reducing workforce by approximately 25%, primarily in early-stage research and development, to save about $15 million annually [7]. - Positive 60-week data from the SPECTRA trial in Diabetic Macular Edema (DME) supports the therapy's tolerability and treatment burden reduction [6][11]. - The 4FRONT-1 trial for wet Age-related Macular Degeneration (AMD) has exceeded initial enrollment projections, with topline data expected in the first half of 2027, accelerated from the second half of 2027 [6][7]. Financial Results - As of June 30, 2025, the company reported cash, cash equivalents, and marketable securities of $417 million, down from $505 million at the end of 2024, primarily due to operational cash usage [8][19]. - Research and development expenses increased to $48.0 million in Q2 2025 from $31.9 million in Q2 2024, driven by the initiation of the Phase 3 clinical trial for 4D-150 [9]. - General and administrative expenses rose to $11.5 million in Q2 2025 from $10.6 million in Q2 2024, mainly due to increased professional services [10]. Expected Milestones - The company anticipates 52-week topline data for the 4FRONT-2 trial in wet AMD in the second half of 2027 [7]. - Data from the PRISM Phase 1/2 clinical trial is expected in Q4 2025 [7]. - The company received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for 4D-150 for DME, indicating potential expedited development [11].